A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME

Diabetic Macular Edema Clinical Trial

Official title:

An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02193113
• Other study ID #: KVD001-001
• Status: Completed
• Phase: Phase 1
• First received: July 9, 2014
• Last updated: March 1, 2017
• Start date: July 18, 2014
• Est. completion date: June 4, 2015

Study information

• Verified date: March 2017
• Source: KalVista Pharmaceuticals, Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1 study to investigate the safety, tolerability of the novel plasma kallikrein inhibitor, KVD001 in subjects with diabetic macular edema. The study is the first step to investigate the hypothesis that plasma kallikrein plays an important role in the disease process behind diabetic macular edema in many patients

Description:

The plasma kallikrein-kinin system has long been recognized as a key player in inflammatory processes, capillary leakage and angiogenesis in various organs. Recent work suggests that plasma kallikrein is central to the pathogenesis of Diabetic Macular Edema (DME) and that activation of the enzyme contributes to the excessive retinal vascular permeability leading to DME. Among different persons with DME, plasma kallikrein contributes both independently in some, and in association with Vascular Endothelial Growth Factor (VEGF) in others. However, the effect of plasma kallikrein appears to be independent of VEGF. Thus, growing scientific evidence points to plasma kallikrein inhibitors as an exciting potential new therapeutic opportunity directed at a novel VEGF-independent pathway that may reduce retinal vascular permeability and treat DME, in patients whose disease process is, at least in part, driven by the plasma kallikrein pathway.

This is an open label, single ascending dose study to investigate the safety, tolerability and pharmacodynamics of a novel plasma kallikrein inhibitor administered by intravitreal (IVT) injection in subjects with central involved diabetic macular edema and reduced vision.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: June 4, 2015
• Est. primary completion date: June 4, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female adult subjects 18 years of age and older

2. Confirmed diagnosis of Type I or Type II diabetes mellitus

3. Best corrected visual acuity, using Early Treatment Diabetic Retinopathy Study (ETDRS) electronic visual acuity (EVA) testing, of between 20/40 and 20/400 (Snellen equivalent) in the study eye

4. Fellow eye acuity 20/80 or better measured as above with no expectation of requirement for anti-VEGF treatment in fellow eye within 2 months of study drug administration

5. Presence of central involved DME in the study eye defined as Optical Coherence Tomography (OCT) Central Subfold Thickness (CST) =305 µm in women and =320 µm in men in the study eye

6. Subjects who fulfil one of the following criteria:

1. Subjects who have not previously received an anti-VEGF treatment and who, in the view of the Investigator, can have initiation of anti-VEGF treatment in the study eye deferred for at least 2 months following the date of anticipated study drug administration

2. Subjects who are receiving regular anti-VEGF intravitreal injections who:

• Have received at least 3 intravitreal injections of an anti-VEGF treatment within the last 5 months (study drug administration will be at least 6 weeks after the most recent intravitreal administration of anti-VEGF) and

• In the view of the Investigator, can have continuation of anti-VEGF treatment in the study eye deferred for at least 2 months following the date of anticipated study drug administration

3. Subjects who have received anti-VEGF in the past (>3 months prior to study inclusion) but are not actively receiving treatment and who in the view of the Investigator, can have resumption of anti-VEGF or alternative treatment in the study eye deferred for at least 2 months following anticipated study drug administration

7. Subjects, who in the view of the Investigator, are not expected to require panretinal laser photocoagulation or intravitreal steroids or intraocular surgery in the study eye for at least 2 months following anticipated study drug administration

8. No prior treatment with panretinal photocoagulation or intravitreal steroid in the study eye within the previous 3 months

9. No prior treatment with systemic corticosteroids or systemic anti-VEGF therapy within the previous 3 months

10. Study participant voluntarily agrees to participate in this study and signs the Institutional Review Board (IRB) approved informed consent prior to performing any procedure

Exclusion Criteria:

1. Females who are pregnant or lactating, or expecting to become pregnant during the course of the study

2. Poorly controlled diabetes mellitus

3. Uncontrolled hypertension

4. Significant co-existing disease

5. Participation in an investigational intervention clinical study within 2 months prior to study inclusion

6. History of alcohol and/or drug abuse in the last 2 years

7. Men not willing to use appropriate birth control methods

8. Media clarity or pupillary dilation inadequate to obtain reasonable quality OCT and/or fundus image

9. Subjects employed by the Sponsor or in any relationship of dependence with the Sponsor and/or Investigator

Related Conditions & MeSH terms

• Diabetic Macular Edema
• Edema
• Macular Edema

Intervention

Drug:
• KVD001 Injection
A novel plasma kallikrein inhibitor

Locations

Country	Name	City	State
United States	Retina Vitreous Associates Medical Group	Beverly Hills	California
United States	Beetham Eye Institute	Boston	Massachusetts
United States	Raj K. Maturi, MD PC	Indianapolis	Indiana
United States	Valley Retina Institute, PA	McAllen	Texas
United States	Palmetto Retina Center	West Columbia	South Carolina

Sponsors (2)

Lead Sponsor	Collaborator
KalVista Pharmaceuticals, Ltd.	Juvenile Diabetes Research Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in retinal thickness from baseline		84 days
Primary	Number of participants with Adverse Events as a measure of safety and tolerability		56 days
Secondary	Measurement of KVD001 plasma levels over time following intravitreal injection (with calculation of Tmax, Cmax, AUC and t1/2)		28 days
Secondary	Best Corrected Visual Acuity as measured by ETDRS EVA		56 days

External Links

•   Sponsor's Website (KalVista Pharmaceuticals)